Actuate Therapeutics, Inc. Increase (Decrease) in Employee Related Liabilities
Actuate Therapeutics, Inc. (ACTU) reported Increase (Decrease) in Employee Related Liabilities of -$201.56 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-14
- Actuate Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was -$499.07K, a 432.20% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was $297.51K, a 14.86% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was -$257.98K, a 129.04% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was -$541.84K.
- Actuate Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2025 was -$300.14K, a 149.13% decline from fiscal 2024.
- Actuate Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2024 was $610.95K, a 319.99% increase from fiscal 2023.
- Actuate Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2023 was $145.47K.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$499.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$201.56K 10-Q · filed 2026-08-14 | -$459.54K derived: sum of 3 quarters · filed 2026-08-14 | -$1.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $297.51K 10-Q · filed 2026-05-14 | $39.53K derived: sum of 2 quarters · filed 2026-05-14 | -$502.31K derived: sum of 3 quarters · filed 2026-05-14 | -$352.07K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$257.98K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$799.81K derived: sum of 2 quarters · filed 2026-03-26 | -$649.58K derived: sum of 3 quarters · filed 2026-08-14 | -$300.14K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$541.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$391.60K derived: sum of 2 quarters · filed 2026-08-14 | -$42.17K 10-Q · filed 2025-11-13 | $846.28K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $150.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $499.67K 10-Q · filed 2026-08-14 | $1.39M derived: sum of 3 quarters · filed 2026-08-14 | $1.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $349.44K 10-Q · filed 2026-05-14 | $1.24M derived: sum of 2 quarters · filed 2026-05-14 | $960.39K derived: sum of 3 quarters · filed 2026-05-14 | $960.39K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $888.45K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $610.95K derived: sum of 2 quarters · filed 2026-03-26 | $610.95K derived: sum of 3 quarters · filed 2026-03-26 | $610.95K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$277.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$277.50K derived: sum of 2 quarters · filed 2025-11-13 | -$277.50K 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $277.50K derived: sum of 3 quarters · filed 2025-08-14 | $277.50K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $277.50K derived: sum of 2 quarters · filed 2025-05-15 | $277.50K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $277.50K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $277.50K derived: sum of 2 quarters · filed 2025-03-13 | $145.47K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$132.03K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$132.03K 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |